Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 PT, Sees Latest FMX114 Data Underscoring "Positive Investment Thesis"

Go back to Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 PT, Sees Latest FMX114 Data Underscoring "Positive Investment Thesis"
(NASDAQ: VYNE) Delayed: 28.56 --0 (-0%)
Previous Close $28.56    52 Week High
Open $28.56    52 Week Low
Day High $28.56    P/E N/A 
Day Low $28.56    EPS
Volume 2,685,854